Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lusduna

- PMLiVE

Eli Lilly partners with breast cancer advocacy organisations to raise awareness of risk factors

More than 290,000 women and men are expected to be diagnosed with breast cancer in the US in 2022

- PMLiVE

Eli Lilly’s Omicron drug treatment gets emergency use authorisation from FDA

The drug can be used to treat adults with mild-to-moderate COVID-19, and children aged 12 or older, in specific emergency cases in non-hospital settings

- PMLiVE

FDA accepts Priority Review for Dupixent in children with moderate-to-severe atopic dermatitis

If approved, Dupixent would be the first biologic treatment available in the US for children aged six months to five years with the skin condition

- PMLiVE

FDA issues approval for Sanofi’s Enjaymo treatment for patients with CAD

The treatment is the first-of-its-kind for patients living with cold agglutinin disease, a rare blood disorder

- PMLiVE

Sanofi unveils new corporate brand and logo

Sanofi Pasteur and Sanofi Genzyme will unite under the new brand image

- PMLiVE

Janssen submits marketing authorisation to EMA for teclistamab

The drug has been developed to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer

- PMLiVE

Lilly reveals $1bn investment in US manufacturing site

The company also plans to invest $500m in a new biopharmaceutical manufacturing facility in Ireland

- PMLiVE

Pfizer’s Paxlovid receives positive opinion from CHMP

If authorised, the drug would be the first COVID-19 oral treatment recommended in the EU

- PMLiVE

Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results

The trial confirms the potential benefit of targeting inflammation in prurigo nodularis

- PMLiVE

Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies

The strategic research collaboration between the two companies aims to develop AI-driven pipeline of precision-engineered therapies

- PMLiVE

Sanofi to pay $1.2bn to acquire Amunix and its ‘stealth’ technology

Sanofi will acquire Amunix’s next-generation protein engineering tech that allows biologic drugs to circulate in ‘stealth’ mode, becoming active only in diseased tissues

- PMLiVE

AstraZeneca’s Saphnelo to be approved in Europe for lupus

The EMA is set to approve the first new treatment for systemic lupus erythematosus in Europe in more than a decade

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links